title: Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure.
abstract: Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally is unclear. We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure.
authors.affiliation: Winthrop-University Hospital, Mineola, New York, USA. sfishbane@metrorenal.com
authors.forename: Steven
authors.initials: S
authors.lastname: Fishbane
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Miyawaki
mesh_terms: D000740:Anemia / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D003920:Diabetes Mellitus; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced* / Q000209:etiology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*; D011994:Recombinant Proteins
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa